Related Experiment Video

Updated: Nov 12, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.9K

Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with

Prateek Lohia1, Shweta Kapur2, Sindhuri Benjaram1

  • 1Department of Internal Medicine, Wayne State University, Detroit, MI, United States.

Journal of Clinical Lipidology
|March 17, 2021
PubMed

Insights

Statins significantly reduced mortality in COVID-19 patients. This study suggests statin use may be beneficial for severe COVID-19 outcomes, warranting further clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Statins are known to reduce inflammation and improve endothelial function.
  • The potential benefits of statins in COVID-19 patients require investigation.

Purpose of the Study:

  • To examine the association between prior statin use and severe outcomes in COVID-19 patients.
  • To assess the impact of statins on mortality, mechanical ventilation, and intensive care unit admission.

Main Methods:

  • Retrospective cohort study of 1014 COVID-19 patients.
  • Comparison of outcomes between statin users and non-users, with propensity score matching.
  • Multivariable regression analysis adjusted for key demographic and clinical confounders.

Main Results:

  • 44.77% of patients were antecedent statin users.
  • Statin use was linked to a significant reduction in mortality in the overall cohort (OR 0.66) and the propensity score-matched cohort (OR 0.56).
  • No significant difference in mechanical ventilation or ICU admission was reported in the abstract.

Conclusions:

  • Antecedent statin use is associated with significantly lower mortality in COVID-19 patients.
  • These findings support further research, including randomized clinical trials, on statins for COVID-19 treatment.
Abstract

Keywords:
COVID-19Critical careHydroxymethylglutaryl-CoA reductase inhibitorsMechanical ventilationMortality

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
110
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
461
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
79
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
114
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
249